Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (9421)	6/4/1998 12:19:00 AM
From: DELT1970	Read Replies (2) \| Respond to of 14328

FROM 1Q CONFERENCE CALL TAPE: Our 5 officer/directors purchased their stock from the options at varying prices in a range of $2.00 down to 0.89 per share. No specifics on who paid what beyond that range. R&D was $600K in the qtr and general expenses were a bit above 1.0 mil. Margins are improving and will continue to do so. EPS growth at 50% remains their stated goal and response to complaints about Wall Street's ambivalence to their stock price. They continue to be unable to predict Unigold FDA approval, but made no comment whatsoever about the reasons for the delay. An analyst from Dublin provoked the most intriguing response related to SmithKline's effort in Africa, where they are launching in South Africa, following test marketing in Nigeria. Sales will expand to all African countries over the next 12 months, and SKB may expand their deal to include other continents, including Europe and the US, should Africa go well. No warrant extension. P, P, and more P is warranted from the Bray point of view, and to them P is also progress.